NCT01043185View on ClinicalTrials.gov

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

AZD3355

30 mg orally in the morning and 30 mg in the evening for 1 day

DRUG

AZD3355

90 mg orally in the morning and 90 mg in the evening for 1 day

DRUG

AZD3355

120 mg orally in the morning and 120 mg in the evening for 1 day

DRUG

AZD3355

240 mg orally in the morning and 240 mg in the evening for 1 day

DRUG

placebo

Placebo capsules orally in the morning and placebo capsules in the evening for 1 day

Trial Locations (1)

Unknown

Research Site, Oklahoma City

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY